摘要
目的探讨奥氮平对首发精神分裂症患者的疗效及认知功能的影响。方法对31例首发精神分裂症患者给予口服奥氮平治疗，观察12w。于治疗前后采用阳性症状量表、阴性症状量表、简明精神病量表评定临床疗效，采用韦氏成人智力量表、韦氏记忆量表、韦斯康星卡片分类测验评定患者的认知功能。结果奥氮平治疗12w末，入组患者阴性症状和阳性症状均有明显改善，不良反应轻微；阳性症状量表、阴性症状量表、简明精神病量表评分均较治疗前显著下降（P〈0．01）；韦斯康星卡片分类测验中的错误应答数较治疗前显著下降（P〈0．01），非持续性错误也有显著下降（P〈0．05）；韦氏记忆量表中的再生、理解、记忆商因子分均显著高于治疗前（P〈0．05）。结论奥氮平治疗精神分裂症疗效显著、安全性高、依从性好，同时又能显著提高患者的部分认知功能。
Objective Toexplore the influences of olanzapine on curative effects and congnitive function of first-episode schizophrenics. Methods 31 first-episode schizophrenics were treated with olanzapine orally for 12 weeks. Curative effects were assessed the Scale for Assessment of Positive Symptom（SAPS）, the Scale for Assessment of Negative Sympton（SANS） and the Brief Psychiatric Rating Scale（BPRS） and cognitive functions with the Wechsler Adult Intelligence Scale（WAIS ）, the Wechsler Memeory Scale（WMS） and Wisconsin Card Sorting Test （WCST） before and after treatment. Results Compared with pretreatment, at the end of 12-week treatment,both negative and positive symptoms of all subjects improved significantly, adverse reactions were mild, scores of the SAPS, SANS,BPRS lowered more significantly （P〈0. 01）; error response numbers of the WCST lowered more significantly（P〈0. 01） and so did non-continuity error （P〈 0.05） ; regeneration, comprehension and memory quotient scores of the WMS were significantly higher（P〈0. 05）. Conclusion Olanzapine has an evident effect, higher safety and better compliance, and meanwhile improves patiens＇ partial eongnitive function notably in the treatment of schizophrenia.
出处
《临床心身疾病杂志》
CAS
2009年第3期242-244,共3页
Journal of Clinical Psychosomatic Diseases
